Table 1.
In vitro anti-malarial activity
| Strain | Compound | (IC50, μM) | Relative IC50 | (CC50, μM) | Selective index(SI) (CC50/IC50) | Relative SI |
|---|---|---|---|---|---|---|
| 3D7 | Chloroquine | 0.014 ± 0.002 | 1.00 | 121.90 ± 8.51 | 8707.10 | 1.00 |
| SKM13 | 0.17 ± 0.01 | 12.14 | 93.11 ± 5.56 | 547.70 | 0.06 | |
| SKM14 | 0.23 ± 0.01 | 16.42 | 47.06 ± 3.21 | 204.16 | 0.02 | |
| FCR3 | Chloroquine | 0.62 ± 0.04 | 1.00 | 121.90 ± 8.51 | 196.60 | 1.00 |
| SKM13 | 0.37 ± 0.01 | 0.60 | 93.11 ± 5.36 | 251.70 | 1.28 | |
| SKM14 | 0.52 ± 0.02 | 0.84 | 47.06 ± 3.21 | 90.50 | 0.46 |
Effects of chloroquine derivatives on the proliferation of CQ-susceptible and resistant strains of P. falciparum
Chloroquine-susceptible (3D7) and -resistant (FCR3) P. falciparum strains were cultured in the presence of increasing concentrations of CQ or each of the CQ derivatives. The values shown are the mean ± standard deviation (SD) from three independent experiments performed in triplicate